Kian Kani | University of Southern California (original) (raw)

Papers by Kian Kani

Research paper thumbnail of Table S4 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines

List of all EGFR pathway associated genes from RNA-seq

Research paper thumbnail of Table S5 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines

Differential CHiP with genes annotation specific for HCC827 Par and ZDR3

Research paper thumbnail of Data from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition

Research paper thumbnail of Protein Mimetic and Anticancer Properties of Monocyte-Targeting Peptide Amphiphile Micelles

ACS Biomaterials Science & Engineering, Oct 16, 2017

Monocyte chemoattractant protein-1 (MCP-1) stimulates the migration of monocytes to inflammatory ... more Monocyte chemoattractant protein-1 (MCP-1) stimulates the migration of monocytes to inflammatory sites, leading to the progression of many diseases. Recently, we described a monocyte-targeting peptide amphiphile micelle (MCP-1 PAM) incorporated with the chemokine receptor CCR2 binding motif of MCP-1, which has a high affinity for monocytes in atherosclerotic plaques. We further report here the biomimetic components of MCP-1 PAMs and the influence of the nanoparticle upon binding to monocytes. We report that MCP-1 PAMs have enhanced secondary structure compared to the MCP-1 peptide. As a result, MCP-1 PAMs displayed improved binding and chemoattractant properties to monocytes, which upregulated the inflammatory signaling pathways responsible for monocyte migration. Interestingly, when MCP-1 PAMs were incubated in the presence of prostate cancer cells in vitro, the particle displayed anticancer efficacy by reducing CCR2 expression. Given that monocytes play an important role in tumor cell migration and invasion, our results demonstrate that PAMs can improve the native *

Research paper thumbnail of Supplementary Figure Legend and Methods from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition

Research paper thumbnail of Supplementary Table 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition

Research paper thumbnail of JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines

Molecular Cancer Therapeutics, Aug 1, 2017

Mutations or deletions in exons 18-21 in the EGFR) are present in approximately 15% of tumors in ... more Mutations or deletions in exons 18-21 in the EGFR) are present in approximately 15% of tumors in patients with nonsmall cell lung cancer (NSCLC). They lead to activation of the EGFR kinase domain and sensitivity to molecularly targeted therapeutics aimed at this domain (gefitinib or erlotinib). These drugs have demonstrated objective clinical response in many of these patients; however, invariably, all patients acquire resistance. To examine the molecular origins of resistance, we derived a set of gefitinib-resistant cells by exposing lung adenocarcinoma cell line, HCC827, with an activating mutation in the EGFR tyrosine kinase domain, to increasing gefitinib concentrations. Gefitinib-resistant cells acquired an increased expression and activation of JUN, a known oncogene involved in cancer progression. Ectopic overexpression of JUN in HCC827 cells increased gefitinib IC 50 from 49 nmol/L to 8 mmol/L (P < 0.001). Downregulation of JUN expression through shRNA resensitized HCC827 cells to gefitinib (IC 50 from 49 nmol/L to 2 nmol/L; P < 0.01). Inhibitors targeting JUN were 3-fold more effective in the gefitinib-resistant cells than in the parental cell line (P < 0.01). Analysis of gene expression in patient tumors with EGFR-activating mutations and poor response to erlotinib revealed a similar pattern as the top 260 differentially expressed genes in the gefitinib-resistant cells (Spearman correlation coefficient of 0.78, P < 0.01). These findings suggest that increased JUN expression and activity may contribute to gefitinib resistance in NSCLC and that JUN pathway therapeutics merit investigation as an alternate treatment strategy. Mol Cancer Ther; 16(8); 1645-57. Ó2017 AACR.

Research paper thumbnail of Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis

Oncogene, Dec 21, 2018

Anterior gradient 2 (AGR2) is a member of the protein disulfide isomerase (PDI) family, which pla... more Anterior gradient 2 (AGR2) is a member of the protein disulfide isomerase (PDI) family, which plays a role in the regulation of protein homeostasis and the unfolded protein response pathway (UPR). AGR2 has also been characterized as a proto-oncogene and a potential cancer biomarker. Cellular localization of AGR2 is emerging as a key component for understanding the role of AGR2 as a proto-oncogene. Here, we provide evidence that extracellular AGR2 (eAGR2) promotes tumor metastasis in various in vivo models. To further characterize the role of the intracellular-resident versus extracellular protein, we performed a comprehensive protein-protein interaction screen. Based on these results, we identify AGR2 as an interacting partner of the mTORC2 pathway. Importantly, our data indicates that eAGR2 promotes increased phosphorylation of RICTOR (T1135), while intracellular AGR2 (iAGR2) antagonizes its levels and phosphorylation. Localization of AGR2 also has opposing effects on the Hippo pathway, spheroid formation, and response to chemotherapy in vitro. Collectively, our results identify disparate phenotypes predicated on AGR2 localization. Our findings also provide credence for screening of eAGR2 to guide therapeutic decisions.

Research paper thumbnail of Precursor-Ion Mass Re-Estimation Improves Peptide Identification on Hybrid Instruments

Journal of Proteome Research, Aug 16, 2008

Mass spectrometry-based proteomics experiments have become an important tool for studying biologi... more Mass spectrometry-based proteomics experiments have become an important tool for studying biological systems. Identifying the proteins in complex mixtures by assigning peptide fragmentation spectra to peptide sequences is an important step in the proteomics process. The 1-2 ppm mass-accuracy of hybrid instruments, like the LTQ-FT, has been cited as a key factor in their ability to identify a larger number of peptides with greater confidence than competing instruments. However, in replicate experiments of an 18-protein mixture, we note parent masses deviate 171 ppm, on average, for ion-trap data directed identifications and 8 ppm, on average, for preview Fourier transform (FT) data directed identifications. These deviations are neither caused by poor calibration nor by excessive ion-loading and are most likely due to errors in parent mass estimation. To improve these deviations, we introduce msPrefix, a program to re-estimate a peptide's parent mass from an associated high-accuracy full-scan survey spectrum. In 18-protein mixture experiments, msPrefix parent mass estimates deviate only 1 ppm, on average, from the identified peptides. In a cell lysate experiment searched with a tolerance of 50 ppm, 2295 peptides were confidently identified using native data and 4560 using msPrefixed data. Likewise, in a plasma experiment searched with a tolerance of 50 ppm, 326 peptides were identified using native data and 1216 using msPrefixed data. msPrefix is also able to determine which MS/MS spectra were possibly derived from multiple precursor ions. In complex mixture experiments, we demonstrate that more than 50% of triggered MS/MS may have had multiple precursor ions and note that spectra with multiple candidate ions are less likely to result in an identification using TANDEM. These results demonstrate integration of msPrefix into traditional shotgun proteomics workflows significantly improves identification results.

Research paper thumbnail of Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells

Endocrine-related Cancer, Apr 1, 2017

Androgen receptor (AR) regulation pathways are essential for supporting the growth and survival o... more Androgen receptor (AR) regulation pathways are essential for supporting the growth and survival of prostate cancer cells. Recently, sub-populations of prostate cancer cells have been identified with stem cell features and are associated with the emergence of treatment-resistant prostate cancer. Here, we explored the function of AR in prostate cancer-associated fibroblasts (CAFs) relative to growth and stem cell-associated characteristics. CAFs were isolated from the murine cPten −/− L prostate cancer model and cultured with human prostate cancer epithelial (hPCa) cells. A murine-specific AR antisense oligonucleotide (ASO) was used to suppress the expression of AR in the CAF cells. CAFs express low, but significant levels of AR relative to fibroblasts derived from non-malignant tissue. CAFs promoted growth and colony formation of hPCa cells, which was attenuated by the suppression of AR expression. Surprisingly, AR-depleted CAFs promoted increased stem cell marker expression in hPCa cells. Interferon gamma (IFN-γ) and macrophage colony-stimulating factor (M-CSF) were increased in AR-depleted CAF cells and exhibited similar effects on stem cell marker expression as seen in the CAF co-culture systems. Clinically, elevated IFN-γ expression was found to correlate with histologic grade in primary prostate cancer samples. In summary, AR and androgendependent signaling are active in CAFs and exert significant effects on prostate cancer cells. IFN-γ and M-CSF are AR-regulated factors secreted by CAF cells, which promote the expression of stem cell markers in prostate cancer epithelial cells. Understanding how CAFs and other constituents of stromal tissue react to anti-cancer therapies may provide insight into the development and progression of prostate cancer.

Research paper thumbnail of Anterior gradient 2 (AGR2): Blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype

The Prostate, Aug 21, 2012

Learning Lie groups for invariant visual perception Rao, Rajesh PN, and Daniel L. Ruderman. "Lear... more Learning Lie groups for invariant visual perception Rao, Rajesh PN, and Daniel L. Ruderman. "Learning Lie groups for invariant visual perception." Advances in neural information processing systems. 1999.

Research paper thumbnail of Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling

Proceedings of the National Academy of Sciences of the United States of America, Jun 25, 2012

Research paper thumbnail of The N-terminal Domains of Neuregulin 1 Confer Signal Attenuation

Journal of Biological Chemistry, Sep 1, 2006

Degradation of activated ERBB receptors is an important mechanism for signal attenuation. However... more Degradation of activated ERBB receptors is an important mechanism for signal attenuation. However, compared with epidermal growth factor (EGF) receptor, the ERBB2/ERBB3 signaling pair is considered to be attenuation-deficient. The ERBB2/ERBB3 ligands of the neuregulin family rely on an EGFlike domain for signaling and are generated from larger membrane-bound precursors. In contrast to EGF, which is processed to yield a 6-kDa peptide ligand, mature neuregulins retain a variety of segments N-terminal to the EGF-like domain. Here we evaluate the role of the N-terminal domain of neuregulin 1 in signaling and turnover of ERBB2/ERBB3. Our data suggest that whereas the EGF-like domain of neuregulin 1 is required and sufficient for the formation of active receptor heterodimers, the presence of the N-terminal Ig-like domain is required for efficient signal attenuation. This manifests itself for both ERBB2 and ERBB3 but is more pronounced and coupled directly to degradation for ERBB3. When stimulated with only the EGF-like domain, ERBB3 shows degradation rates comparable with constitutive turnover, but stimulation with full-length neuregulin 1 resulted in receptor degradation at rates that are comparable with activated EGF receptor. Most of the enhancement in downregulation was maintained after replacing the Ig-like domain with a thioredoxin protein of comparable size but different amino acid composition, suggesting that the physical presence but not specific properties of the Ig-like domain are needed. This sequence-independent effect of the N-terminal domain correlates with an enhanced ability of full-size neuregulin 1 to disrupt higher order oligomers of the ERBB3 extracellular domains in vitro.

Research paper thumbnail of Supplementary Figure 4 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition

PDF file, 131KB, Basal levels protein biomarkers. Basal levels of EpCAM, ELAVL1, and CBFB demonst... more PDF file, 131KB, Basal levels protein biomarkers. Basal levels of EpCAM, ELAVL1, and CBFB demonstrate a correlation to gefitinib sensitivity. Non-treated NSCLC lysates, synchronized by serum starvation for 16 hours, were generated and assayed for basal protein levels by Western blot.

Research paper thumbnail of Supplementary Figure 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition

Research paper thumbnail of Table S2 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines

Affinity Purification of EGFR, JUN, JNK, and FOS

Research paper thumbnail of Supplemental Materials and Methods from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines

Supplemental text, figures, and data

Research paper thumbnail of Table S1 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines

Quantitative Proteomics Data

Research paper thumbnail of Table S3 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines

Top 260 deferentially expressed genes in HCC827 and HCC827ZDR3

Research paper thumbnail of Supplementary Figure 2 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition

Research paper thumbnail of Table S4 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines

List of all EGFR pathway associated genes from RNA-seq

Research paper thumbnail of Table S5 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines

Differential CHiP with genes annotation specific for HCC827 Par and ZDR3

Research paper thumbnail of Data from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition

Research paper thumbnail of Protein Mimetic and Anticancer Properties of Monocyte-Targeting Peptide Amphiphile Micelles

ACS Biomaterials Science & Engineering, Oct 16, 2017

Monocyte chemoattractant protein-1 (MCP-1) stimulates the migration of monocytes to inflammatory ... more Monocyte chemoattractant protein-1 (MCP-1) stimulates the migration of monocytes to inflammatory sites, leading to the progression of many diseases. Recently, we described a monocyte-targeting peptide amphiphile micelle (MCP-1 PAM) incorporated with the chemokine receptor CCR2 binding motif of MCP-1, which has a high affinity for monocytes in atherosclerotic plaques. We further report here the biomimetic components of MCP-1 PAMs and the influence of the nanoparticle upon binding to monocytes. We report that MCP-1 PAMs have enhanced secondary structure compared to the MCP-1 peptide. As a result, MCP-1 PAMs displayed improved binding and chemoattractant properties to monocytes, which upregulated the inflammatory signaling pathways responsible for monocyte migration. Interestingly, when MCP-1 PAMs were incubated in the presence of prostate cancer cells in vitro, the particle displayed anticancer efficacy by reducing CCR2 expression. Given that monocytes play an important role in tumor cell migration and invasion, our results demonstrate that PAMs can improve the native *

Research paper thumbnail of Supplementary Figure Legend and Methods from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition

Research paper thumbnail of Supplementary Table 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition

Research paper thumbnail of JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines

Molecular Cancer Therapeutics, Aug 1, 2017

Mutations or deletions in exons 18-21 in the EGFR) are present in approximately 15% of tumors in ... more Mutations or deletions in exons 18-21 in the EGFR) are present in approximately 15% of tumors in patients with nonsmall cell lung cancer (NSCLC). They lead to activation of the EGFR kinase domain and sensitivity to molecularly targeted therapeutics aimed at this domain (gefitinib or erlotinib). These drugs have demonstrated objective clinical response in many of these patients; however, invariably, all patients acquire resistance. To examine the molecular origins of resistance, we derived a set of gefitinib-resistant cells by exposing lung adenocarcinoma cell line, HCC827, with an activating mutation in the EGFR tyrosine kinase domain, to increasing gefitinib concentrations. Gefitinib-resistant cells acquired an increased expression and activation of JUN, a known oncogene involved in cancer progression. Ectopic overexpression of JUN in HCC827 cells increased gefitinib IC 50 from 49 nmol/L to 8 mmol/L (P < 0.001). Downregulation of JUN expression through shRNA resensitized HCC827 cells to gefitinib (IC 50 from 49 nmol/L to 2 nmol/L; P < 0.01). Inhibitors targeting JUN were 3-fold more effective in the gefitinib-resistant cells than in the parental cell line (P < 0.01). Analysis of gene expression in patient tumors with EGFR-activating mutations and poor response to erlotinib revealed a similar pattern as the top 260 differentially expressed genes in the gefitinib-resistant cells (Spearman correlation coefficient of 0.78, P < 0.01). These findings suggest that increased JUN expression and activity may contribute to gefitinib resistance in NSCLC and that JUN pathway therapeutics merit investigation as an alternate treatment strategy. Mol Cancer Ther; 16(8); 1645-57. Ó2017 AACR.

Research paper thumbnail of Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis

Oncogene, Dec 21, 2018

Anterior gradient 2 (AGR2) is a member of the protein disulfide isomerase (PDI) family, which pla... more Anterior gradient 2 (AGR2) is a member of the protein disulfide isomerase (PDI) family, which plays a role in the regulation of protein homeostasis and the unfolded protein response pathway (UPR). AGR2 has also been characterized as a proto-oncogene and a potential cancer biomarker. Cellular localization of AGR2 is emerging as a key component for understanding the role of AGR2 as a proto-oncogene. Here, we provide evidence that extracellular AGR2 (eAGR2) promotes tumor metastasis in various in vivo models. To further characterize the role of the intracellular-resident versus extracellular protein, we performed a comprehensive protein-protein interaction screen. Based on these results, we identify AGR2 as an interacting partner of the mTORC2 pathway. Importantly, our data indicates that eAGR2 promotes increased phosphorylation of RICTOR (T1135), while intracellular AGR2 (iAGR2) antagonizes its levels and phosphorylation. Localization of AGR2 also has opposing effects on the Hippo pathway, spheroid formation, and response to chemotherapy in vitro. Collectively, our results identify disparate phenotypes predicated on AGR2 localization. Our findings also provide credence for screening of eAGR2 to guide therapeutic decisions.

Research paper thumbnail of Precursor-Ion Mass Re-Estimation Improves Peptide Identification on Hybrid Instruments

Journal of Proteome Research, Aug 16, 2008

Mass spectrometry-based proteomics experiments have become an important tool for studying biologi... more Mass spectrometry-based proteomics experiments have become an important tool for studying biological systems. Identifying the proteins in complex mixtures by assigning peptide fragmentation spectra to peptide sequences is an important step in the proteomics process. The 1-2 ppm mass-accuracy of hybrid instruments, like the LTQ-FT, has been cited as a key factor in their ability to identify a larger number of peptides with greater confidence than competing instruments. However, in replicate experiments of an 18-protein mixture, we note parent masses deviate 171 ppm, on average, for ion-trap data directed identifications and 8 ppm, on average, for preview Fourier transform (FT) data directed identifications. These deviations are neither caused by poor calibration nor by excessive ion-loading and are most likely due to errors in parent mass estimation. To improve these deviations, we introduce msPrefix, a program to re-estimate a peptide's parent mass from an associated high-accuracy full-scan survey spectrum. In 18-protein mixture experiments, msPrefix parent mass estimates deviate only 1 ppm, on average, from the identified peptides. In a cell lysate experiment searched with a tolerance of 50 ppm, 2295 peptides were confidently identified using native data and 4560 using msPrefixed data. Likewise, in a plasma experiment searched with a tolerance of 50 ppm, 326 peptides were identified using native data and 1216 using msPrefixed data. msPrefix is also able to determine which MS/MS spectra were possibly derived from multiple precursor ions. In complex mixture experiments, we demonstrate that more than 50% of triggered MS/MS may have had multiple precursor ions and note that spectra with multiple candidate ions are less likely to result in an identification using TANDEM. These results demonstrate integration of msPrefix into traditional shotgun proteomics workflows significantly improves identification results.

Research paper thumbnail of Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells

Endocrine-related Cancer, Apr 1, 2017

Androgen receptor (AR) regulation pathways are essential for supporting the growth and survival o... more Androgen receptor (AR) regulation pathways are essential for supporting the growth and survival of prostate cancer cells. Recently, sub-populations of prostate cancer cells have been identified with stem cell features and are associated with the emergence of treatment-resistant prostate cancer. Here, we explored the function of AR in prostate cancer-associated fibroblasts (CAFs) relative to growth and stem cell-associated characteristics. CAFs were isolated from the murine cPten −/− L prostate cancer model and cultured with human prostate cancer epithelial (hPCa) cells. A murine-specific AR antisense oligonucleotide (ASO) was used to suppress the expression of AR in the CAF cells. CAFs express low, but significant levels of AR relative to fibroblasts derived from non-malignant tissue. CAFs promoted growth and colony formation of hPCa cells, which was attenuated by the suppression of AR expression. Surprisingly, AR-depleted CAFs promoted increased stem cell marker expression in hPCa cells. Interferon gamma (IFN-γ) and macrophage colony-stimulating factor (M-CSF) were increased in AR-depleted CAF cells and exhibited similar effects on stem cell marker expression as seen in the CAF co-culture systems. Clinically, elevated IFN-γ expression was found to correlate with histologic grade in primary prostate cancer samples. In summary, AR and androgendependent signaling are active in CAFs and exert significant effects on prostate cancer cells. IFN-γ and M-CSF are AR-regulated factors secreted by CAF cells, which promote the expression of stem cell markers in prostate cancer epithelial cells. Understanding how CAFs and other constituents of stromal tissue react to anti-cancer therapies may provide insight into the development and progression of prostate cancer.

Research paper thumbnail of Anterior gradient 2 (AGR2): Blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype

The Prostate, Aug 21, 2012

Learning Lie groups for invariant visual perception Rao, Rajesh PN, and Daniel L. Ruderman. "Lear... more Learning Lie groups for invariant visual perception Rao, Rajesh PN, and Daniel L. Ruderman. "Learning Lie groups for invariant visual perception." Advances in neural information processing systems. 1999.

Research paper thumbnail of Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling

Proceedings of the National Academy of Sciences of the United States of America, Jun 25, 2012

Research paper thumbnail of The N-terminal Domains of Neuregulin 1 Confer Signal Attenuation

Journal of Biological Chemistry, Sep 1, 2006

Degradation of activated ERBB receptors is an important mechanism for signal attenuation. However... more Degradation of activated ERBB receptors is an important mechanism for signal attenuation. However, compared with epidermal growth factor (EGF) receptor, the ERBB2/ERBB3 signaling pair is considered to be attenuation-deficient. The ERBB2/ERBB3 ligands of the neuregulin family rely on an EGFlike domain for signaling and are generated from larger membrane-bound precursors. In contrast to EGF, which is processed to yield a 6-kDa peptide ligand, mature neuregulins retain a variety of segments N-terminal to the EGF-like domain. Here we evaluate the role of the N-terminal domain of neuregulin 1 in signaling and turnover of ERBB2/ERBB3. Our data suggest that whereas the EGF-like domain of neuregulin 1 is required and sufficient for the formation of active receptor heterodimers, the presence of the N-terminal Ig-like domain is required for efficient signal attenuation. This manifests itself for both ERBB2 and ERBB3 but is more pronounced and coupled directly to degradation for ERBB3. When stimulated with only the EGF-like domain, ERBB3 shows degradation rates comparable with constitutive turnover, but stimulation with full-length neuregulin 1 resulted in receptor degradation at rates that are comparable with activated EGF receptor. Most of the enhancement in downregulation was maintained after replacing the Ig-like domain with a thioredoxin protein of comparable size but different amino acid composition, suggesting that the physical presence but not specific properties of the Ig-like domain are needed. This sequence-independent effect of the N-terminal domain correlates with an enhanced ability of full-size neuregulin 1 to disrupt higher order oligomers of the ERBB3 extracellular domains in vitro.

Research paper thumbnail of Supplementary Figure 4 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition

PDF file, 131KB, Basal levels protein biomarkers. Basal levels of EpCAM, ELAVL1, and CBFB demonst... more PDF file, 131KB, Basal levels protein biomarkers. Basal levels of EpCAM, ELAVL1, and CBFB demonstrate a correlation to gefitinib sensitivity. Non-treated NSCLC lysates, synchronized by serum starvation for 16 hours, were generated and assayed for basal protein levels by Western blot.

Research paper thumbnail of Supplementary Figure 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition

Research paper thumbnail of Table S2 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines

Affinity Purification of EGFR, JUN, JNK, and FOS

Research paper thumbnail of Supplemental Materials and Methods from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines

Supplemental text, figures, and data

Research paper thumbnail of Table S1 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines

Quantitative Proteomics Data

Research paper thumbnail of Table S3 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines

Top 260 deferentially expressed genes in HCC827 and HCC827ZDR3

Research paper thumbnail of Supplementary Figure 2 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition